For the quarter ending 2025-09-30, CTKB made $52,293K in revenue. -$5,478K in net income. Net profit margin of -10.48%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue, net | 52,293 | 45,602 | 41,457 | 51,168 |
| Service | - | 6,814 | - | - |
| Product | - | 14,921 | - | - |
| Total cost of sales | 24,742 | 21,735 | 21,300 | 22,836 |
| Gross profit | 27,551 | 23,867 | 20,157 | 28,333 |
| Research and development | 8,956 | 8,826 | 9,725 | 9,760 |
| Sales and marketing | 11,666 | 12,134 | 12,509 | 12,209 |
| General and administrative | 16,121 | 13,531 | 12,898 | 10,239 |
| Total operating expenses | 36,743 | 34,491 | 35,132 | 32,207 |
| Loss from operations | -9,192 | -10,624 | -14,975 | -3,874 |
| Interest expense | 494 | 414 | 291 | -2,746 |
| Interest income | 573 | 555 | 508 | 1,136 |
| Other income, net | 1,344 | 3,708 | 3,492 | 657 |
| Total other income, net | 1,423 | 3,849 | 3,709 | 4,539 |
| (loss) income before income taxes | -7,769 | -6,775 | -11,266 | 665 |
| Benefit from income taxes | -2,291 | -1,192 | 136 | -1,072 |
| Net loss | - | -5,583 | - | - |
| Net (loss) income | -5,478 | - | -11,402 | 1,737 |
| Net (loss) income, basic | -5,478 | -5,583 | -11,402 | 1,737 |
| Weighted-average shares used in calculating net (loss) income per share, basic(in shares) | 127,547,859 | 126,934,294 | 128,339,481 | -65,916,450 |
| Weighted-average shares used in calculating net (loss) income per share, diluted (in shares) | 127,547,859 | 126,934,294 | 128,339,481 | -66,807,354 |
Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)